Enavatuzumab: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 10:26, 24 October 2011 editBeetstra (talk \| contribs)Edit filter managers, Administrators172,055 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').← Previous edit		Latest revision as of 10:45, 19 November 2023 edit undoEntranced98 (talk \| contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,119 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper
(12 intermediate revisions by 10 users not shown)
Line 1:		Line 1:
			{{Short description\|Monoclonal antibody}}
	{{Drugbox		{{Drugbox
	\| Verifiedfields = changed		\| Verifiedfields = changed
			\| Watchedfields = changed
	\| verifiedrevid = ~~449166871~~		\| verifiedrevid = 457124199
	\| type = mab		\| type = mab
	\| image =		\| image =
Line 14:		Line 16:
	\| pregnancy_US = <!-- A / B / C / D / X -->		\| pregnancy_US = <!-- A / B / C / D / X -->
	\| pregnancy_category=		\| pregnancy_category=
	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->		\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
	\| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->		\| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
	\| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->		\| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
Line 25:		Line 27:
	\| elimination_half-life =		\| elimination_half-life =
	\| excretion =		\| excretion =
	\| CAS_number_Ref = {{cascite\|~~correct~~\|??}}		\| CAS_number_Ref = {{cascite\|changed\|CAS}}
	\| CAS_number = <!-- ~~blanked - oldvalue: 912628-39-8 -->~~		\| CAS_number = 1062149-33-0
			\| UNII_Ref = {{fdacite\|changed\|FDA}}
			\| UNII = 914910XFBB
	\| ATC_prefix = none		\| ATC_prefix = none
	\| ATC_suffix =		\| ATC_suffix =
	\| PubChem =		\| PubChem =
	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}		\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
	\| DrugBank =		\| DrugBank =
	\| C=6334 \| H=9792 \| N=1700 \| O=2000 \| S=42		\| C=6334 \| H=9792 \| N=1700 \| O=2000 \| S=42
	\| molecular_weight = 143.1 kDa
	\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}		\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}
	\| ChemSpiderID = NA		\| ChemSpiderID = none
			\| KEGG = D09896
	}}		}}

			'''Enavatuzumab''' is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the ].<ref name="pmid29054986">{{cite journal \| vauthors = Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D \| display-authors = 6 \| title = Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors \| journal = Molecular Cancer Therapeutics \| volume = 17 \| issue = 1 \| pages = 215–221 \| date = January 2018 \| pmid = 29054986 \| pmc = 5752572 \| doi = 10.1158/1535-7163.MCT-17-0330 }}</ref>
	'''Enavatuzumab''' is a humanized monoclonal antibody used in the treatment of solid tumors.

	Enavatuzumab was developed by Facet Biotech Corp.<ref>{{cite web\|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab\|publisher=]\|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref>		Enavatuzumab was developed by Facet Biotech Corp.<ref>{{cite web\|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab\|publisher=]\|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref>

	== References ==		==References==
			{{reflist\|30em}}

		⚫	{{Monoclonals for tumors}}
	<references/>
			{{Cytokine receptor modulators}}

			]
⚫	{{~~monoclonals~~ for tumors}}

Latest revision as of 10:45, 19 November 2023

Monoclonal antibody Pharmaceutical compound

Enavatuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	TWEAK receptor
Clinical data
ATC code	none
Identifiers
CAS Number	1062149-33-0
ChemSpider	none
UNII	914910XFBB
KEGG	D09896
Chemical and physical data
Formula	C₆₃₃₄H₉₇₉₂N₁₇₀₀O₂₀₀₀S₄₂
Molar mass	143104.43 g·mol
(what is this?) (verify)

Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor.

Enavatuzumab was developed by Facet Biotech Corp.

References

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, et al. (January 2018). "Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors". Molecular Cancer Therapeutics. 17 (1): 215–221. doi:10.1158/1535-7163.MCT-17-0330. PMC 5752572. PMID 29054986.
"Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab" (PDF). American Medical Association.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab Amivantamab Ascrinvacumab Atezolizumab (+hyaluronidase) Balstilimab Botensilimab Cixutumumab Conatumumab Cosibelimab Daratumumab Drozitumab Duligotumab Dusigitumab Enfortumab vedotin Enoticumab Figitumumab Flanvotumab Ganitumab Glembatumumab vedotin Intetumumab Ipilimumab Iratumumab Istiratumab Icrucumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Nesvacumab Nivolumab (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab Panitumumab Patritumab Pembrolizumab Pritumumab Radretumab Ramucirumab Rilotumumab Robatumumab Seribantumab Sugemalimab Tarextumab Tisotumab vedotin Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab Bavituximab Brentuximab vedotin Carotuximab Cetuximab Derlotuximab biotin Dinutuximab Ecromeximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine Brontictuzumab Cantuzumab mertansine Cantuzumab ravtansine Cirmtuzumab Citatuzumab bogatox Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab Demcizumab Dalotuzumab Denintuzumab mafodotin Elotuzumab Emactuzumab Emibetuzumab Enoblituzumab Epcoritamab Etaracizumab Farletuzumab Ficlatuzumab Flotetuzumab Gemtuzumab ozogamicin Glofitamab Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lifastuzumab vedotin Lintuzumab Lorvotuzumab mertansine Lumretuzumab Matuzumab Milatuzumab Naxitamab Nimotuzumab Obinutuzumab Ocaratuzumab Odronextamab Otlertuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Pinatuzumab vedotin Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine Sacituzumab govitecan Sibrotuzumab Simtuzumab Sofituzumab vedotin Tacatuzumab tetraxetan Tigatuzumab Trastuzumab (+deruxtecan / +emtansine) Tucotuzumab celmoleukin Vandortuzumab vedotin Vanucizumab Veltuzumab Vorsetuzumab mafodotin Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab
Chimeric + humanized	Depatuxizumab mafodotin Duvortuxizumab Ontuxizumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Cytokine receptor modulators

Chemokine

See here instead.

CSF

Erythropoietin	Agonists: ARA-290 Asialo erythropoietin Carbamylated erythropoietin CNTO-530 Darbepoetin alfa Epoetin alfa Epoetin beta Epoetin delta Epoetin epsilon Epoetin gamma Epoetin kappa Epoetin omega Epoetin theta Epoetin zeta Erythropoietin (EPO) Erythropoietin-Fc Methoxy polyethylene glycol-epoetin beta (CERA/Mircera) Peginesatide Pegol sihematide (EPO-018B)
G-CSF (CSF3)	Agonists: Filgrastim Granulocyte colony-stimulating factor Lenograstim Leridistim Lipegfilgrastim Nartograstim Pegfilgrastim Pegnartograstim
GM-CSF (CSF2)	Agonists: Ecogramostim Granulocyte macrophage colony-stimulating factor Milodistim Molgramostim Regramostim Sargramostim Antibodies: Mavrilimumab Namilumab Otilimab
M-CSF (CSF1)	Agonists: Cilmostim Interleukin-34 Lanimostim Macrophage colony-stimulating factor Mirimostim Kinase inhibitors: Agerafenib
SCF (c-Kit)	See here instead.
Thrombopoietin	Agonists: Eltrombopag Pegacaristim Promegapoietin Romiplostim Thrombopoietin (THPO, MGDF)

Interferon

IFNAR (α/β, I)

Decoy receptors: Bifarcept

IFNGR (γ, II)

Agonists: Interferon gamma (IFN-γ)
Interferon gamma 1b

Antibodies: Emapalumab
Fontolizumab

IFNLR (λ, III)

See IL-28R (IFNLR) here instead.

Interleukin

See here instead.

TGFβ

See here instead.

TNF

See here instead.

Others

JAK
(inhibitors)

JAK1	Abrocitinib Baricitinib Deuruxolitinib Filgotinib Momelotinib Oclacitinib Peficitinib Ruxolitinib Tofacitinib (tasocitinib) Upadacitinib
JAK2	Atiprimod AZD-1480 Baricitinib CHZ868 Cucurbitacin I (elatericin B, JSI-124) CYT387 Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994 Pacritinib Peficitinib Ruxolitinib SD-1008 Tofacitinib (tasocitinib)
JAK3	Cercosporamide Decernotinib (VX-509) Peficitinib Ritlecitinib TCS-21311 Tofacitinib (tasocitinib) WHI-P 154 ZM-39923 ZM-449829
TYK2	Deucravacitinib

Others

Additional cytokines: Cardiotrophin 1 (CT-1)
FMS-like tyrosine kinase 3 ligand (FLT3L)
Leukemia/leukocyte inhibitory factor (LIF)
Oncostatin M (OSM)
Thymic stromal lymphopoietin (TSLP)

Additional cytokine receptor modulators: Emfilermin
Lestaurtinib
Midostaurin
Quizartinib
Sorafenib
Sunitinib

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: